CTI BioPharma: Surges after starting late-stage trial on severe COVID-19 patients

CTI Biopharma

27/04/2020 13:15

** Shares of drug developer  CTIC.O  jump 20% to $1.06 -
among top pct gainers across U.S. exchanges
    ** Co starts late-stage trial to test investigational oral
kinase inhibitor, pacritinib, in hospitalized patients with
severe COVID-19  urn:newsml:reuters.com:*:nPn9w811Ta
    ** The trial will assess the drug plus standard of care 358
hospitalized patients - CTIC
    ** Main goal of study will be to assess proportion of
patients who progress to invasive mechanical ventilation to
those who die by Day 28 - CTIC
    ** Co expects to start enrollment in U.S. and Europe with
data expected by end of 2020
    ** CTIC had fallen 44.2% YTD, as of last close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))